JP2023512519A5 - - Google Patents
Info
- Publication number
- JP2023512519A5 JP2023512519A5 JP2022546341A JP2022546341A JP2023512519A5 JP 2023512519 A5 JP2023512519 A5 JP 2023512519A5 JP 2022546341 A JP2022546341 A JP 2022546341A JP 2022546341 A JP2022546341 A JP 2022546341A JP 2023512519 A5 JP2023512519 A5 JP 2023512519A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- inventions
- nucleic acid
- protein
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (43)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969008P | 2020-01-31 | 2020-01-31 | |
| US62/969,008 | 2020-01-31 | ||
| US202062994630P | 2020-03-25 | 2020-03-25 | |
| US62/994,630 | 2020-03-25 | ||
| US202063014467P | 2020-04-23 | 2020-04-23 | |
| US63/014,467 | 2020-04-23 | ||
| US202063025782P | 2020-05-15 | 2020-05-15 | |
| US63/025,782 | 2020-05-15 | ||
| US202062705187P | 2020-06-15 | 2020-06-15 | |
| US62/705,187 | 2020-06-15 | ||
| US202062705308P | 2020-06-21 | 2020-06-21 | |
| US62/705,308 | 2020-06-21 | ||
| US202063043090P | 2020-06-23 | 2020-06-23 | |
| US63/043,090 | 2020-06-23 | ||
| US202062706366P | 2020-08-12 | 2020-08-12 | |
| US62/706,366 | 2020-08-12 | ||
| US202063066147P | 2020-08-14 | 2020-08-14 | |
| US63/066,147 | 2020-08-14 | ||
| US202062706676P | 2020-09-02 | 2020-09-02 | |
| US62/706,676 | 2020-09-02 | ||
| US202062706937P | 2020-09-18 | 2020-09-18 | |
| US62/706,937 | 2020-09-18 | ||
| US202062706958P | 2020-09-21 | 2020-09-21 | |
| US62/706,958 | 2020-09-21 | ||
| US202063198089P | 2020-09-28 | 2020-09-28 | |
| US63/198,089 | 2020-09-28 | ||
| US202063198306P | 2020-10-09 | 2020-10-09 | |
| US63/198,306 | 2020-10-09 | ||
| US202063112900P | 2020-11-12 | 2020-11-12 | |
| US63/112,900 | 2020-11-12 | ||
| CA3101131A CA3101131A1 (en) | 2020-01-31 | 2020-11-28 | Compositions and methods for preventing and treating coronavirus infection - sarscov-2 vaccines |
| CA3101131 | 2020-11-28 | ||
| US202063121482P | 2020-12-04 | 2020-12-04 | |
| US63/121,482 | 2020-12-04 | ||
| US202163133969P | 2021-01-05 | 2021-01-05 | |
| US63/133,969 | 2021-01-05 | ||
| US202163135182P | 2021-01-08 | 2021-01-08 | |
| US63/135,182 | 2021-01-08 | ||
| US202163141913P | 2021-01-26 | 2021-01-26 | |
| US63/141,913 | 2021-01-26 | ||
| US202163142977P | 2021-01-28 | 2021-01-28 | |
| US63/142,977 | 2021-01-28 | ||
| PCT/US2021/015946 WO2021155323A1 (en) | 2020-01-31 | 2021-01-30 | Compositions and methods for preventing and treating coronavirus infection-sars-cov-2 vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023512519A JP2023512519A (ja) | 2023-03-27 |
| JP2023512519A5 true JP2023512519A5 (https=) | 2024-02-07 |
Family
ID=77079265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022546341A Withdrawn JP2023512519A (ja) | 2020-01-31 | 2021-01-30 | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11498944B2 (https=) |
| EP (1) | EP4097122A4 (https=) |
| JP (1) | JP2023512519A (https=) |
| KR (1) | KR20220134622A (https=) |
| CN (1) | CN116096732A (https=) |
| BR (1) | BR112022014808A2 (https=) |
| TW (1) | TW202204380A (https=) |
| UY (1) | UY39060A (https=) |
| WO (1) | WO2021155323A1 (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210260181A1 (en) * | 2014-09-16 | 2021-08-26 | Altimmune, Inc | Coronavirus immunogenic compositions and uses thereof |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US12029786B2 (en) | 2020-02-07 | 2024-07-09 | RNAimmune, Inc. | Composition and method of mRNA vaccines against novel coronavirus infection |
| CA3167611A1 (en) | 2020-02-13 | 2021-08-19 | Etienne Simon-Loriere | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| IL295548A (en) * | 2020-02-14 | 2022-10-01 | Altimmune Inc | Immunogenic compositions of the corona virus and their uses |
| EP4103231A4 (en) | 2020-02-14 | 2024-03-27 | Geovax, Inc. | VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2 |
| GB2594683A (en) * | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
| JP2023511780A (ja) | 2020-02-25 | 2023-03-22 | イノビオ ファーマシューティカルズ，インコーポレイティド | コロナウイルスに対するワクチンおよび使用方法 |
| US11213482B1 (en) * | 2020-03-05 | 2022-01-04 | University of Pittsburgh—Of the Commonwealth System of Higher Educat | SARS-CoV-2 subunit vaccine and microneedle array delivery system |
| IL297419B2 (en) | 2020-04-22 | 2025-02-01 | BioNTech SE | Coronavirus vaccine |
| EP4143348A4 (en) * | 2020-04-29 | 2024-01-17 | Lu, Shi-Long | VIRAL TEST IN SALIVA |
| US12226431B2 (en) | 2021-09-11 | 2025-02-18 | Porosome Therapeutics, Inc. | Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| IL298333A (en) * | 2020-05-20 | 2023-01-01 | Alexandru Adrian Hennrich | A viral assembly vector for a vaccine against the corona virus cell |
| CA3170740A1 (en) * | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| WO2021245611A1 (en) * | 2020-06-05 | 2021-12-09 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
| WO2021249011A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Hiv vaccine compositions, methods, and uses thereof |
| WO2021249116A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Coronavirus vaccine compositions, methods, and uses thereof |
| WO2022008973A2 (en) * | 2020-07-10 | 2022-01-13 | Covid Diagnostics Ltd. | Compositions, methods, and systems for detecting immune response |
| US11740240B2 (en) * | 2020-07-20 | 2023-08-29 | Bio-Rad Laboratories, Inc. | Immunoassay for SARS-CoV-2 neutralizing antibodies and materials therefor |
| WO2022025264A1 (ja) * | 2020-07-31 | 2022-02-03 | 東亞合成株式会社 | ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用 |
| US20220193225A1 (en) * | 2020-08-31 | 2022-06-23 | Bruce Lyday | Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins |
| WO2022041760A1 (en) | 2020-08-31 | 2022-03-03 | Sichuan Clover Biopharmaceuticals, Inc. | Methods and compositions for purification of trimeric fusion proteins |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| US20220226489A1 (en) * | 2021-01-20 | 2022-07-21 | Singh Biotechnology, Llc | Therapeutics directed against coronavirus |
| JP7598538B2 (ja) * | 2021-01-29 | 2024-12-12 | 東亞合成株式会社 | ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用 |
| JP2024511463A (ja) | 2021-03-22 | 2024-03-13 | リコード セラピューティクス，インク． | 細胞への標的送達のための組成物および方法 |
| CA3213221A1 (en) * | 2021-03-22 | 2022-09-29 | Gale Smith | Coronavirus vaccine formulations |
| CA3213107A1 (en) | 2021-03-23 | 2022-09-29 | Mirko HENNIG | Polynucleotide compositions, related formulations, and methods of use thereof |
| US20220324918A1 (en) * | 2021-03-30 | 2022-10-13 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE ECTODOMAIN POLYPEPTIDES AND COMPOSITIONS AND METHODS THEREOF |
| US20220370598A1 (en) * | 2021-05-05 | 2022-11-24 | Inovio Pharmaceuticals, Inc. | Vaccines Against Coronavirus and Methods of Use |
| US20220370600A1 (en) * | 2021-05-21 | 2022-11-24 | Board Of Regents, The University Of Texas System | Multigenic mva-sars-cov-2 vaccine |
| JP2024530672A (ja) | 2021-08-11 | 2024-08-23 | アールエヌエーイミューン、インコーポレイテッド | 新規なコロナウイルス感染症に対するｍＲＮＡワクチンの組成物および方法 |
| CN113832168B (zh) * | 2021-08-15 | 2023-08-04 | 北京科兴中维生物技术有限公司 | mRNA疫苗及其制备方法和应用 |
| WO2023020939A1 (en) * | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023023940A1 (zh) * | 2021-08-24 | 2023-03-02 | 复旦大学 | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 |
| WO2023026182A1 (en) | 2021-08-24 | 2023-03-02 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| CN116041448B (zh) * | 2021-08-26 | 2025-05-13 | 江苏瑞科生物技术股份有限公司 | 新型冠状病毒免疫原性物质、其制备方法和应用 |
| CN113913464B (zh) * | 2021-09-28 | 2022-11-22 | 武汉枢密脑科学技术有限公司 | 一种表达载体、重组腺相关病毒及其在制备2019新型冠状病毒疫苗中的应用 |
| WO2023092100A2 (en) * | 2021-11-19 | 2023-05-25 | Meissa Vaccines, Inc. | Methods of administering chimeric vaccines |
| CN116178527B (zh) * | 2021-11-26 | 2025-12-09 | 深圳先进技术研究院 | 抗sars-cov-2全人源单克隆抗体6g18及其制法与应用 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US20250025549A1 (en) * | 2021-11-30 | 2025-01-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| TWI843471B (zh) * | 2022-03-11 | 2024-05-21 | 財團法人國家衛生研究院 | 含抗原和dna之組成物及其用途 |
| CN114574502B (zh) * | 2022-04-11 | 2023-07-14 | 四川大学 | 一种以复制缺陷腺相关病毒为载体的新型冠状病毒疫苗 |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
| TW202400635A (zh) * | 2022-04-20 | 2024-01-01 | 美商因諾維奧製藥公司 | 針對sars-cov-2變異體之免疫原性組合物及其使用方法 |
| WO2023212446A1 (en) * | 2022-04-29 | 2023-11-02 | Xequel Bio, Inc. | Compositions and methods for treating complications of viral infections and other respiratory disorders |
| WO2023240278A2 (en) * | 2022-06-10 | 2023-12-14 | The Trustees Of Columbia University In The City Of New York | Uses of glycolipids as a vaccine adjuvant and methods thereof |
| WO2023250111A1 (en) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Combination therapies for the treatment of viral infections |
| US11654121B1 (en) | 2022-06-22 | 2023-05-23 | Flagship Pioneering Innovations Vi, Llc | Combination therapies for the treatment of viral infections |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| JP2025523631A (ja) * | 2022-07-07 | 2025-07-23 | 成都威斯克生物医▲薬▼有限公司 | Ｓａｒｓ－ｃｏｖ－２又はその変異体の感染に抵抗するための医薬組成物及びその併用薬剤 |
| CN118119646A (zh) * | 2022-08-08 | 2024-05-31 | 神州细胞工程有限公司 | 一种可诱导广谱中和活性重组五组分新冠病毒三聚体蛋白疫苗的制备及应用 |
| KR20250120970A (ko) * | 2022-10-07 | 2025-08-11 | 젭토메트릭스 엘엘씨 | 단백질 기반 분석을 위한 대조군 |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| US12280104B2 (en) | 2022-11-01 | 2025-04-22 | RNAimmune, Inc. | Composition and methods for MRNA vaccines against novel omicron coronavirus infections |
| CN116024269B (zh) * | 2022-11-18 | 2024-02-02 | 复百澳(苏州)生物医药科技有限公司 | 一种冠状病毒假病毒颗粒的制备方法 |
| CN116077635B (zh) * | 2022-11-23 | 2026-03-20 | 珠海市丽珠单抗生物技术有限公司 | 新型冠状病毒融合蛋白疫苗其应用 |
| CN116585465B (zh) * | 2023-04-19 | 2025-12-30 | 山东兴瑞生物科技有限公司 | 一种雾化吸入新冠疫苗及其制备方法 |
| WO2024229195A1 (en) * | 2023-05-03 | 2024-11-07 | Partner Therapeutics, Inc. | Viral infection modulation in vaccinated subjects treated with granulocyte-macrophage colony-stimulating factor (gm-csf) |
| EP4704881A2 (en) * | 2023-05-03 | 2026-03-11 | Partner Therapeutics, Inc. | Humoral modulation in vaccinated and virally infected subjects with granulocyte-macrophage colony-stimulating factor (gm-csf) |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| DE69233158T2 (de) | 1991-03-07 | 2004-05-13 | Connaught Technology Corp., Greenville | Gentechnologisch hergestellter stamm für impfstoffe |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US5801030A (en) | 1995-09-01 | 1998-09-01 | Genvec, Inc. | Methods and vectors for site-specific recombination |
| FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| IL137510A0 (en) | 1998-02-17 | 2001-07-24 | Schering Corp | Compositions comprising viruses and methods for concentrating virus preparations |
| DK1133316T3 (da) | 1998-11-16 | 2009-05-25 | Introgen Therapeutics Inc | Adenovirus-formulering til genterapi |
| US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| ES2284545T3 (es) | 1999-11-16 | 2007-11-16 | Genzyme Corporation | Vectores y transgenes con elementos reguladores para la administracion de genes del higado. |
| JP5118798B2 (ja) | 2000-03-07 | 2013-01-16 | メルク・シャープ・エンド・ドーム・コーポレイション | アデノウイルス製剤 |
| ATE437221T1 (de) | 2001-05-14 | 2009-08-15 | Gbp Ip Llc | Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie |
| CA2469623C (en) | 2001-12-12 | 2012-05-29 | F H Faulding & Co Limited | Composition for the preservation of viruses |
| AR038153A1 (es) | 2002-01-18 | 2004-12-29 | Schering Ag | Formulaciones estabilizadas de adenovirus |
| US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
| SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| WO2005005596A2 (en) | 2003-06-18 | 2005-01-20 | Chinese National Human Genome Center At Shanghai | Characterization of the earliest stages of the severe acute respiratory syndrome (sars) virus and uses thereof |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| SG128680A1 (en) | 2003-07-22 | 2007-01-30 | Crucell Holland Bv | Binding molecules against sars-coronavirus and uses thereof |
| US20070270361A1 (en) * | 2003-08-04 | 2007-11-22 | Shan Lu | Sars Nucleic Acids, Proteins, Vaccines, and Uses Thereof |
| US7129042B2 (en) * | 2003-11-03 | 2006-10-31 | Diagnostic Hybrids, Inc. | Compositions and methods for detecting severe acute respiratory syndrome coronavirus |
| US20070116716A1 (en) * | 2003-12-10 | 2007-05-24 | Shuo Shen | Sars coronavirus s proteins and uses thereof |
| DE602005017743D1 (de) | 2004-01-23 | 2009-12-31 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| AP2351A (en) | 2004-10-13 | 2012-01-25 | Crucell Holland Bv | Improved adenoviral vectors and uses thereof. |
| JP2008521575A (ja) | 2004-12-01 | 2008-06-26 | ジェンザイム・コーポレイション | 肝臓を標的とした遺伝物質の送達方法 |
| CN101969996A (zh) | 2005-08-23 | 2011-02-09 | 加利福尼亚大学董事会 | 多价疫苗 |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| EP1998804B1 (en) | 2006-03-27 | 2014-04-16 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
| US10041049B2 (en) | 2008-11-03 | 2018-08-07 | Janssen Vaccines & Prevention B.V. | Method for the production of adenoviral vectors |
| NZ602504A (en) | 2008-11-18 | 2014-01-31 | Beth Israel Hospital | Antiviral vaccines with improved cellular immunogenicity |
| PL2391638T3 (pl) | 2009-02-02 | 2018-11-30 | Glaxosmithkline Biologicals Sa | Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania |
| WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| MX2012007936A (es) | 2010-02-15 | 2012-11-22 | Crucell Holland Bv | Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus. |
| DK2655604T3 (en) | 2010-12-14 | 2018-08-06 | Us Gov Health & Human Services | ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES |
| GB201108879D0 (en) | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
| JP5805908B2 (ja) * | 2012-03-22 | 2015-11-10 | クルセル ホランド ベー ヴェー | Ｒｓｖに対するワクチン |
| US10960070B2 (en) | 2016-10-25 | 2021-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
| US11034978B2 (en) | 2017-02-09 | 2021-06-15 | Janssen Vaccines & Prevention B.V. | Potent and short promoter for expression of heterologous genes |
| EP3595676A4 (en) * | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | RNA VACCINES AGAINST ZOONOSES |
| GB201708444D0 (en) | 2017-05-26 | 2017-07-12 | Univ Oxford Innovation Ltd | Compositions and methods for inducing an immune response |
| WO2019086461A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus vectors and uses thereof |
| WO2019086466A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| CN111372943B (zh) | 2017-10-31 | 2023-12-05 | 扬森疫苗与预防公司 | 腺病毒及其用途 |
| RU2709659C1 (ru) * | 2018-09-06 | 2019-12-19 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Иммунобиологическое средство и способ его использования для индукции специфического иммунитета к вирусу ближневосточного респираторного синдрома (варианты) |
| US10953089B1 (en) * | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| JP2023511633A (ja) * | 2020-01-28 | 2023-03-20 | モデルナティエックス インコーポレイテッド | コロナウイルスｒｎａワクチン |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| KR20230009466A (ko) * | 2020-05-11 | 2023-01-17 | 얀센 파마슈티칼즈, 인코포레이티드 | SARS-CoV-2 백신 |
| US10906944B2 (en) | 2020-06-29 | 2021-02-02 | The Scripps Research Institute | Stabilized coronavirus spike (S) protein immunogens and related vaccines |
-
2021
- 2021-01-30 JP JP2022546341A patent/JP2023512519A/ja not_active Withdrawn
- 2021-01-30 WO PCT/US2021/015946 patent/WO2021155323A1/en not_active Ceased
- 2021-01-30 BR BR112022014808A patent/BR112022014808A2/pt not_active IP Right Cessation
- 2021-01-30 KR KR1020227030114A patent/KR20220134622A/ko not_active Withdrawn
- 2021-01-30 US US17/163,357 patent/US11498944B2/en active Active
- 2021-01-30 CN CN202180025856.2A patent/CN116096732A/zh active Pending
- 2021-01-30 EP EP21747489.9A patent/EP4097122A4/en not_active Withdrawn
- 2021-01-30 TW TW110103610A patent/TW202204380A/zh unknown
- 2021-01-30 US US17/759,803 patent/US20230075527A1/en not_active Abandoned
- 2021-02-01 UY UY0001039060A patent/UY39060A/es unknown
- 2021-07-28 US US17/387,105 patent/US11384122B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023512519A5 (https=) | ||
| US20230381301A1 (en) | Respiratory virus nucleic acid vaccines | |
| US8137931B2 (en) | Fusion proteins of HIV regulatory/accessory proteins | |
| US10059747B2 (en) | Crimean-congo haemorrhagic fever virus antigenic composition | |
| CN116059336A (zh) | 针对rsv的疫苗 | |
| JP2023513720A5 (https=) | ||
| WO2021042944A1 (zh) | 肌肉靶向的微环dna基因治疗 | |
| JP2025508676A5 (https=) | ||
| JP2025084850A (ja) | ハンタウイルス抗原性組成物 | |
| JP2023528984A (ja) | コロナウイルス病に対する組換え修飾ワクシニアウイルスアンカラ（ｍｖａ）ワクチン | |
| WO2019076882A1 (en) | ADENOVIRAL VECTORS COMPRISING TWO EXPRESSION CASSETTES ENCODING RSV ANTIGENIC PROTEINS OR FRAGMENTS THEREOF | |
| CN114375199A (zh) | 非洲猪瘟疫苗 | |
| CN110382518B (zh) | 用于血清型a型口蹄疫病毒的嵌合疫苗 | |
| WO2025180455A1 (en) | A circular rna vaccine against herpes zoster virus and the use thereof | |
| WO2024245344A1 (zh) | 预防新型冠状病毒奥密克戎突变株的mRNA疫苗 | |
| WO2024105539A1 (en) | Recombinant lsdv vectored bovine coronavirus antigen constructs | |
| JP2024521364A5 (https=) | ||
| HK1104307A (en) | Fusion protein of hiv regulatory/accessory proteins | |
| HK1076822B (en) | Fusion protein of hiv regulatory/accessory proteins | |
| HK1111704A (en) | Fusion protein of hiv regulatory/accessory proteins |